BuqitongluO Granule for Qi Deficiency and Blood Stasis Syndrome

Summary

The main purpose of this trial is to evaluate the efficacy and safety of Buqitongluo Granule in treating qi deficiency and blood stasis syndrome, and explore the effect of the improvement of qi deficiency and blood stasis syndrome on the prognosis of diseases.

Conditions

• Stroke, Ischemic
• Coronary Artery Disease
• Angina Pectoris, Stable
• Diabetic Peripheral Neuropathy

Interventions

DRUG

Buqitongluo Granule

Buqitongluo Granules were dissolved with boiled water, administered orally, each bag of 10 grams, one bag each time, three times a day for 42 days.

DRUG

Buqitongluo Granule Placebo

Buqitongluo Granule placeboes were dissolved with boiled water, administered orally, each bag of 10 grams, one bag each time, three times a day for 42 days.

OTHER

Standard care

Guidelines-based standard care for convalescence of ischemic stroke, stable angina pectoris of coronary artery disease or diabetic peripheral neuropathy.

Sponsors & Collaborators

• The Affiliated Hospital of Changchun University of Chinese Medicine

  collaborator UNKNOWN

• The Affiliated Hospital of Shandong University of Chinese Medicine

  collaborator UNKNOWN

• The Affiliated Hospital of Chengdu University of Chinese Medicine

  collaborator UNKNOWN

• The Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine

  collaborator UNKNOWN

• The First Affiliated Hospital of Heilongjiang University of Traditional Chinese Medicine

  collaborator UNKNOWN

• The Second Affiliated Hospital of Heilongjiang University of Traditional Chinese Medicine

  collaborator UNKNOWN

• The Second Affiliated Hospital of Hunan University of Traditional Chinese Medicine

  collaborator OTHER

• Hunan Academy of Traditional Chinese Medicine Affiliated Hospital

  collaborator UNKNOWN

• The First Clinical Hospital of Jilin Academy of Traditional Chinese Medicine

  collaborator UNKNOWN

• Shaanxi Buchang Pharmaceuticals Co., Ltd.

  collaborator UNKNOWN

• Beijing Chuanglikechuang Medical Technology Development Co., Ltd.

  collaborator UNKNOWN

• Shanghai Youningwei Biotechnology Co., Ltd.

  collaborator UNKNOWN

• Wuhan Zhizhi Medical Technology Co., Ltd.

  collaborator UNKNOWN

• Wuhan Third Hospital

  collaborator OTHER

• Rizhao Hospital of Traditional Chinese Medicine

  collaborator UNKNOWN

• The First Affiliated Hospital of Guangxi University of Traditional Chinese Medicine

  collaborator UNKNOWN

• Jiangbin Hospital of Guangxi Zhuang Autonomous Region

  collaborator UNKNOWN

• Dongzhimen Hospital, Beijing

  lead OTHER

Principal Investigators

• Ying Gao, MD · Dongzhimen Hospital

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Model

PARALLEL

Eligibility

Min Age

35 Years

Max Age

80 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2020-07-22

Primary Completion

2022-12-31

Completion

2022-12-31

Countries

• China

Study Locations